A multicenter, randomized, double-blind, placebo-controlled Phase Ib clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of MWN105 injection in overweight or obese participants who are intolerant to semaglutide
Latest Information Update: 11 Sep 2025
At a glance
- Drugs Obesity therapies (Primary)
- Indications Obesity
- Focus Adverse reactions
- Acronyms CTR20253330; MWN105-Ib-WL
Most Recent Events
- 11 Sep 2025 New trial record